Risperidone mesylate

Research use only, not for human use.

An antipsychotic agent with serotonin-S2 and dopamine-D2 antagonistic properties.

An antipsychotic agent with serotonin-S2 and dopamine-D2 antagonistic properties; also has actions at several 5-HT receptor subtypes, adrenergic receptors and histamine H1 receptors.Schizophrenia Approved.

Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively. Risperidone dose-dependently inhibited the release of IL-12 in mature DCs, while the production of IL-10 is dose-dependently increased by Risperidone. A high dose of risperidone can induce TNF-α release from mature DCs.

In the first experiment, body weight is found to be slightly but significantly lower in the Risperidone-treated rats as a function of age. Similar to the first experiment, age-dependent differences in body weight are also observed between the three treatment groups in the second locomotor experiment. Rats treated with the 3.0 mg/kg dose of Risperidone weigh less than vehicle-treated rats on postnatal days 35, 38, and 41. The third locomotor experiment involves larger, mixed-sex litters in contrast to the smaller, single-sex litters used in the first two experiments. As noted for the first two experiments, rats treated with Risperidone in the third experiment gain less weight in an age-dependent manner.

Apexidone | R-64766 | R64766

GPCR/G Protein

5-HT Receptor

5-HT Receptor

Neurological Disease

Schizophrenia

666179-96-0

506.5901

C24H31FN4O5S

>98% (HPLC)

10 mM in DMSO

O=C1C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)=C(C)N=C5N1CCCC5.OS(=O)(C)=O

4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years